Bronchitis is nothing but the inflammation of the lining of bronchial tubes of the lungs. It is of two types, namely, acute and chronic bronchitis. Acute bronchitis, also known as a chest cold, is found to be very common and develops from a cold or other respiratory infection. On the other hand, chronic bronchitis is a severe condition which is characterized by constant irritation or inflammation of the lining of bronchial tubes. It is included in the Chronic Obstructive Pulmonary Disease (COPD). Shortness of breath, cough, slight fever and chills, production of mucus, fatigue, and chest discomfort are major symptoms of bronchitis. It can be diagnosed through various tests such as chest X-ray, sputum tests, and pulmonary function test.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5758
The global bronchitis market is mainly driven by the increasing prevalence of lung diseases such as bronchitis, asthma, COPD, availability of drugs for the treatment, and drugs. Additionally, increasing number of diagnostic services for various chronic diseases and the use of technologically advanced devices for diagnosis also drive the growth of the market. Other factors supporting the market growth are an addiction to smoking and changing lifestyle. However, fierce competition among the existing market players restrains the growth of the market.
The global bronchitis market growth is expected to boost at a CAGR of 5.3% during the forecast period.
The global bronchitis market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into acute bronchitis and chronic bronchitis.
On the basis of diagnosis, the market is segmented into chest X-ray, sputum tests, and pulmonary function tests.
On the basis of treatment, the market is segmented into drugs and oxygen therapy. Drugs is further segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics.
On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, research institutes, and others.
Regional Analysis of the Global Bronchitis Market
The American bronchitis market is segmented into two regions, namely, North America and South America. North America is the largest market with huge patient pool, growing awareness about bronchitis treatment among the people and presence of major players in the market. South America is expected to be the fastest growing market with the increasing demand for diagnostic services.
In Europe, the bronchitis market is driven by the increasing focus on research and development activities for the treatment of chronic bronchitis. Germany and the U.K. occupy a first and second position in the European market which is driven by the increasing demand for diagnostic services for respiratory diseases and the emergence of new players in the market manufacturing various classes of drugs in the market.
The bronchitis market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing environmental population, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases among the adults. Additionally, growth in the number of people addicted to smoking and increasing number of patients with COPD fuel the market in this region.
The Middle Eastern and African market for bronchitis exhibits a steady rise with the growing awareness about causes, diagnosis, and treatment of chronic diseases. The demand for primary care services including diagnostic services for respiratory diseases fuels the market growth in Africa.
Key Players in the Global Bronchitis Market
Some of the key players in this market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bronchitis-market-5758